! # Ola via Alexandros G.Sfakianakis on Inoreader

Πέμπτη 2 Νοεμβρίου 2017

Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer.

Related Articles

Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer.

Support Care Cancer. 2017 Oct 31;:

Authors: Bubalo JS, Herrington JD, Takemoto M, Willman P, Edwards MS, Williams C, Fisher A, Palumbo A, Chen E, Blanke C, Lopez CD

Abstract
PURPOSE: Chemotherapy-induced nausea and vomiting (CINV) causes significant morbidity among colorectal cancer patients, receiving fluorouracil, oxaliplatin, and leucovorin (FOLFOX) chemotherapy even with standard antiemetic prophylaxis. The purpose of this study is to determine if the addition of aprepitant to standard antiemetic therapy improves CINV in these patients.
METHODS: Patients receiving FOLFOX for colorectal cancer were given antiemetic prophylaxis with aprepitant 125 mg orally on day 1 and 80 mg on days 2 and 3. Palonosetron 0.25 mg was given IV push on day 1 only. Dexamethasone 12 mg was administered orally on day 1 and 8 mg each morning on days 2 through 4. Assessments including emetic events, rescue doses, nutritional intake, and appetite were recorded in a patient diary which was returned to study personnel in the following cycle.
RESULTS: Of the 53 patients screened, 50 were evaluable and had a complete dataset for cycle 1. For the first cycle, 74% of patients achieved a complete response (CR), 22% achieved a major response and 4% experienced treatment failure. The percentage of patients achieving a CR remained high throughout each cycle at 83, 83, and 86% for cycles 2, 3, and 4, respectively. Appetite and nutritional status remained largely unchanged throughout treatment. Adverse events occurring in more than 10% of patients included diarrhea (13.6%), fatigue (12.6%), and neutropenia (11%).
CONCLUSIONS: Aprepitant added to standard antiemetic therapy appears to be an effective and safe regimen for prevention of CINV in patients receiving FOLFOX.

PMID: 29090385 [PubMed - as supplied by publisher]



from C via xlomafota.13 on Inoreader http://ift.tt/2xOXToD
via IFTTT

1 σχόλιο:

  1. I want to share with you all on how Dr Itua saves my life with his powerful Herbal medicines, I was diagnosed of Oral/Ovarian Cancer which i suffered from for 5 years with no positive treatment until when My son came to me in the hospital when i was laying down on my dying bed waiting for god to call out my name to join him in heaven.
    My son was so excited that very day he came across Dr Itua on Blogspot, we decided to give him a try although we Americans are so scared to trust Africans but i really have no choice that time to choose life in between so we gave a try to Dr Itua Herbal medicines, god wiling he was a good man with a god gift. Dr Itua send us the herbal medicine it was three bottles. I take it for three weeks instructor and this herbal medicines heal me, cure my Oral/Ovarian Cancer completely I have been living for 9 months now with healthy life no more symptoms.
    I'm sponsoring Dr Itua in LA Advert on Cancer patent seminar which my son will be participating too and other patent Dr Itua has cured from all kind of human disease, also if you are sick from disease like,Epilepsy,Breast Cancer,Prostate Cancer,Throat cancer,Thyroid Cancer,Uterine cancer,Fibroid,Angiopathy, Ataxia,Arthritis,Brain cancer,Hiv,. Vaginal cancer,Herpes,Colon-Rectal Cancer,Chronic Disease.Amyotrophic Lateral Scoliosis,Brain Tumor,Fibromyalgia,Fluoroquinolone Toxicity,Multiple myeloma,Tach Diseases,Leukemia,Liver cancer,
    Esophageal cancer,Gallbladder cancer,,Bladder cancer,Gestational trophoblastic disease,Head and neck cancer,Hodgkin lymphoma
    Intestinal cancer,Kidney cancer,Hpv,Lung cancer,Adrenal cancer.Bile duct cancer,Bone cancer,Melanoma,Mesothelioma,Neuroendocrine tumors
    Non-Hodgkin lymphoma,Cervical Cancer,Oral cancer,Hepatitis,Skin cancer,Soft tissue sarcoma,Spinal cancer,Pancreatic Cancer, Stomach cancer
    Testicular cancer,
    Syndrome Fibrodysplasia Ossificans ProgresSclerosis,Alzheimer's disease,Chronic Diarrhea,Copd,Parkinson,Als,Adrenocortical carcinoma Infectious mononucleosis,Vulvar cancer,Ovarian cancer,,Sinus cancer, Here Is The Wonderful Healer Contact. Name_ Doctor Itua, Email Contact: drituaherbalcenter@gmail.com, Phone/WhatsApp: +2348149277967

    ΑπάντησηΔιαγραφή